stockportfolio.pro
Zoetis Inc. (ZTS)
Healthcare · Drug Manufacturers - Specialty & Generic · NYSE
Zoetis Inc. revenue & earnings — last 10 fiscal years
| Metric | 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | $4.89B | $5.31B | $5.83B | $6.26B | $6.67B | $7.78B | $8.08B | $8.54B | $9.26B | $9.47B |
| Gross profit | $3.22B | $3.53B | $3.91B | $4.27B | $4.62B | $5.47B | $5.63B | $5.98B | $6.54B | $6.80B |
| Net income | $821.00M | $864.00M | $1.43B | $1.50B | $1.64B | $2.04B | $2.11B | $2.34B | $2.49B | $2.67B |
| Net margin | 16.8% | 16.3% | 24.5% | 24.0% | 24.5% | 26.2% | 26.2% | 27.4% | 26.9% | 28.2% |
Source: Zoetis Inc. SEC filings (10-K). 15 years of history available in the interactive view.
What growth is priced into ZTS stock?
At today's market cap of $34.46B, Zoetis Inc. is priced for free-cash-flow growth of about 3.9% per year for 10 years (assuming a 10% discount rate and 2.5% terminal growth, base FCF $2.28B from the FY ending 2025-12-31). For comparison, free cash flow actually grew 6.4%/yr over the last five fiscal years and revenue 7.2%/yr, computed from its SEC filings. This is a reverse DCF — a translation of the price into a growth assumption you can judge, not a fair value and not advice. Change the assumptions yourself in the interactive view →
Explore 15 years of Zoetis Inc. financials — interactive
Full income statement, balance sheet and cash flow with CAGR and trend on every row, 48 quarters, valuation ratios, plain-English health checks, and Ask — our SEC-grounded research assistant.
Open the interactive view — freeOr start a 7-day free trial to track ZTS in your portfolio →
Zoetis Inc. financial history by metric
About Zoetis Inc.
Zoetis Inc. engages in the discovery, development, manufacture, and commercialization of medicines, vaccines, diagnostic products and services, biodevices, genetic tests, and precision animal health solutions for the animal health industry in the United States and internationally. The company commercializes products primarily across companion animals comprising dogs, cats, and horses; and species, including livestock, such as cattle, swine, poultry, fish, and sheep. It also offers parasiticides, vaccines, dermatology, anti-infectives, pain and sedation, other pharmaceutical, and animal health diagnostics. In addition, the company provides animal health diagnostics, including point-of-care diagnostic products, instruments and reagents, rapid immunoassay tests, reference laboratory kits and services, and blood glucose monitors; and other non-pharmaceutical products, which include nutritionals, as well as products and services in biodevices, genetic tests, and precision animal health. It markets its products to veterinarians, livestock producers, and pet owners. The company has collaborated with Blacksmith Medicines, Inc. to discover and develop novel antibiotics for animal health. Zoetis Inc. was incorporated in 2012 and is headquartered in Parsippany, New Jersey.
Zoetis Inc. — frequently asked questions
What is Zoetis Inc.'s revenue?
Zoetis Inc. (ZTS) reported revenue of $9.47B for fiscal year 2025, up 2.3% from the prior year, according to its SEC filings.
Is Zoetis Inc. profitable?
Yes. ZTS earned net income of $2.67B in fiscal 2025, a net margin of 28.2%.
What is ZTS's P/E ratio?
Zoetis Inc. trades at a price-to-earnings ratio of about 13.5 based on the latest data in our nightly-refreshed cache.
How fast is Zoetis Inc. growing?
ZTS's revenue grew at roughly 7.2% per year over the last five fiscal years (compound annual growth rate), computed from SEC-filed statements.
How much debt does Zoetis Inc. have?
As of fiscal year 2025, ZTS carried roughly $9.04B in total debt (short- plus long-term borrowings), per its filed balance sheet.
What is Zoetis Inc.'s gross margin?
ZTS's gross margin was 71.8% in fiscal 2025 — gross profit of $6.80B on revenue of $9.47B.
What is Zoetis Inc.'s market cap?
Zoetis Inc. (ZTS) has a market capitalization of about $34.46B, based on the latest data in our nightly-refreshed cache.
When does Zoetis Inc.'s fiscal year end?
ZTS's fiscal year ends in December. Its most recent annual filing covers the fiscal year ending 2025-12-31.
What growth is priced into ZTS stock?
At today's market cap of $34.46B, Zoetis Inc. is priced for free-cash-flow growth of about 3.9% per year for 10 years (assuming a 10% discount rate and 2.5% terminal growth, base FCF $2.28B from the FY ending 2025-12-31). For comparison, free cash flow actually grew 6.4%/yr over the last five fiscal years and revenue 7.2%/yr, computed from its SEC filings.
Where does this data come from?
All figures are computed from Zoetis Inc.'s official SEC filings (10-K and 10-Q), covering 15 years of history, refreshed nightly. stockportfolio.pro does not provide investment advice.